Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Every batch is analysed in-house by HPLC and mass spectrometry and ships with a Certificate of Analysis
There was a 2015 Phase I human trial registered to study safety and pharmacokinetics, but published results are conspicuously missing
Key benefits Why people compare it 1 FDA-approved as Egrifta for visceral adipose tissue reduction in lipodystrophy 2 15-18% VAT reduction demonstrated in two Phase 3 trials (N=816) 3 Improved triglycerides and waist circumference in key clinical data 4 Extended half-life (26-38 min) vs sermorelin due to trans-3-hexenoic acid modification 5 Improved verbal memory and executive function in older adults (Neurology study, p=0.03) 6 Physiological GH stimulation with intact pituitary negative feedback 7 Demonstrated 32% hepatic fat reduction in 12-month NAFLD trial 8 Well-characterized safety profile through FDA approval and post-marketing surveillance Deep research About Tesamorelin Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of all 44 amino acids of native GHRH with a trans-3-hexenoic acid moiety conjugated to the tyrosine residue at position 1 via a carbamate linker
Medical professionals must diagnose the deficiency accurately before giving the go-ahead
US$ 21.02
US$ 24.76
US$ 20.42
US$ 26.03
US$ 27.29
US$ 27.66
US$ 28.23
